Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue

被引：13

作者：

Antinozzi, Cristina ^{[1
]}

Sgro, Paolo ^{[1
]}

Di Luigi, Luigi ^{[1
]}

机构：

[1] Univ Rome Foro Italico, Dept Movement Human & Hlth Sci, Unit Endocrinol, I-00135 Rome, Italy

来源：

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY | 2020年 / 2020卷

关键词：

ACTIVATED PROTEIN-KINASE; IMPROVES INSULIN SENSITIVITY; PDE5; INHIBITORS; NITRIC-OXIDE; SKELETAL-MUSCLE; ENDOTHELIAL FUNCTION; ERECTILE DYSFUNCTION; DIABETES-MELLITUS; AMP KINASE; SILDENAFIL;

D O I：

10.1155/2020/7078108

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Among metabolic diseases, carbohydrate metabolism disorders are the most widespread. The most common glucose pathological conditions are acquired and may increase the risk of type 2 diabetes, obesity, heart diseases, stroke, and kidney insufficiency. Phosphodiesterase type 5 inhibitors (PDE5i) have long been used as an effective therapeutic option for the treatment of erectile dysfunction (ED). Different studies have demonstrated that PDE5i, by sensitizing insulin target tissues to insulin, play an important role in controlling the action of insulin and glucose metabolism, highlighting the protective action of these drugs against metabolic diseases. In this review, we report the latest knowledge about the role of PDE5i in the metabolic diseases of insulin resistance and type 2 diabetes, highlighting clinical aspects and potential treatment approaches. Although various encouraging data are available, further in vivo and in vitro studies are required to elucidate the mechanism of action and their clinical application in humans.

引用

页数：8

共 84 条

[1]

Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality [J].

Anderson, Simon G. ;

Hutchings, David C. ;

Woodward, Mark ;

Rahimi, Kazem ;

Rutter, Martin K. ;

Kirby, Mike ;

Hackett, Geoff ;

Trafford, Andrew W. ;

Heald, Adrian H. .

HEART, 2016, 102 (21) :1750-1756

[2]

Phosphodiesterase type 5 (PDE5) in the adipocyte: a novel player in fat metabolism? [J].

Armani, Andrea ;

Marzolla, Vincenzo ;

Rosano, Giuseppe M. C. ;

Fabbri, Andrea ;

Caprio, Massimiliano .

TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2011, 22 (10) :404-411

[3]

Association between fasting glucose and C-reactive protein in middle-aged subjects [J].

Aronson, D ;

Bartha, P ;

Zinder, O ;

Kerner, A ;

Shitman, E ;

Markiewicz, W ;

Brook, GJ ;

Levy, Y .

DIABETIC MEDICINE, 2004, 21 (01) :39-44

[4]

Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes [J].

Aversa, A. ;

Vitale, C. ;

Volterrani, M. ;

Fabbri, A. ;

Spera, G. ;

Fini, M. ;

Rosano, G. M. C. .

DIABETIC MEDICINE, 2008, 25 (01) :37-44

[5]

Tadalafil improves lean mass and endothelial function in nonobese men with mild ED/LUTS: in vivo and in vitro characterization [J].

Aversa, Antonio ;

Fittipaldi, Simona ;

Francomano, Davide ;

Bimonte, Viviana M. ;

Greco, Emanuela A. ;

Crescioli, Clara ;

Di Luigi, Luigi ;

Lenzi, Andrea ;

Migliaccio, Silvia .

ENDOCRINE, 2017, 56 (03) :639-648

[6]

Systemic and metabolic effects of PDE5-inhibitor drugs [J].

Aversa, Antonio .

WORLD JOURNAL OF DIABETES, 2010, 1 (01) :3-7

[7]

Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice [J].

Ayala, Julio E. ;

Bracy, Deanna P. ;

Julien, Brianna M. ;

Rottman, Jeffrey N. ;

Fueger, Patrick T. ;

Wasserman, David H. .

DIABETES, 2007, 56 (04) :1025-1033

[8]

Balhara Yatan Pal Singh, 2015, Indian J Endocrinol Metab, V19, P451, DOI 10.4103/2230-8210.159023

[9]

Acute exposure to AICAR increases glucose transport in mouse EDL and soleus muscle [J].

Balon, TW ;

Jasman, AP .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 282 (04) :1008-1011

[10]

New treatment options for erectile dysfunction in patients with diabetes mellitus [J].

Basu, A ;

Ryder, REJ .

DRUGS, 2004, 64 (23) :2667-2688

← 1 2 3 4 5 6 7 8 9 →